Advertisement

Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica

  • Dario CamellinoEmail author
  • Andrea Giusti
  • Giuseppe Girasole
  • Gerolamo Bianchi
  • Christian Dejaco
Review Article
  • 48 Downloads

Abstract

Polymyalgia rheumatica is an inflammatory rheumatic disease of the elderly characterised by pain and stiffness in the neck and pelvic girdle, and is the second most common inflammatory rheumatic condition in this age group, after rheumatoid arthritis. Polymyalgia rheumatica can occur independently or in association with giant cell arteritis, which is the most common form of primary vasculitis. The diagnosis of polymyalgia rheumatica is usually based on clinical presentation and increase of inflammatory markers. There are no pathognomonic findings that can confirm the diagnosis. However, different imaging techniques, especially ultrasonography, can assist in the identification of polymyalgia rheumatica. Glucocorticoids are the cornerstone of the treatment of polymyalgia rheumatica, but they might be associated with different adverse events. A subgroup of patients presents with a refractory disease course and, in these cases, adding methotrexate as a steroid-sparing agent could be useful. In this review, we summarise the latest findings regarding the pathogenesis, diagnosis and management of polymyalgia rheumatica and try to highlight the possible pitfalls, especially in elderly patients.

Notes

Compliance with Ethical Standards

Funding

No sources of funding or writing assistance were received for the preparation of this article.

Conflict of interest

Dario Camellino has received consultancy and speaker fees from AbbVie, Celgene, Janssen-Cilag, Lilly, Mylan and Sanofi; none related to this article. Andrea Giusti has received consultancy and speaker fees from Abiogen, Amgen, EffRx, Eli Lilly, Internis, Labatec, NewBridge, PharmaLink and UCB; none related to this article. Giuseppe Girasole has received speaker fees from Abiogen; none related to this article. Gerolamo Bianchi has received honoraria and/or consulting fees from Abbvie, Abiogen, Alfa-Sigma, Amgen, BMS, Celgene, Chiesi, Eli Lilly, GSK, Janssen, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi Genzyme and Servier. Christian Dejaco has received consultancy fees and honoraria from AbbVie, Celgene, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz and UCB and unrestricted grant support from Celgene.

References

  1. 1.
    Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315(22):2442–58.CrossRefPubMedGoogle Scholar
  2. 2.
    Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Steel L, Khan A, Dasgupta B. Giant cell arteritis: beyond corticosteroids. Drugs Aging. 2015;32(8):591–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Raheel S, Shbeeb I, Crowson CS, Matteson EL. Epidemiology of polymyalgia rheumatica 2000–2014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res (Hoboken). 2017;69(8):1282–5.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cimmino MA, Caporali R, Montecucco CM, Rovida S, Baratelli E, Broggini M. A seasonal pattern in the onset of polymyalgia rheumatica. Ann Rheum Dis. 1990;49(7):521–3.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hysa S, Sobrero A, Camellino D, Pizzorni C, Cutolo M, Cimmino MA. A seasonal onset for polymyalgia rheumatica? Clin Exp Rheumatol. 2018;36(1 Suppl. 109):S28.Google Scholar
  7. 7.
    Brault C, Riis AH, Mor A, Duhaut P, Thomsen RW. Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study. Clin Epidemiol. 2018;10:1533–43.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cimmino MA, Camellino D. Large vessel vasculitis: is it more common than usually assumed? Reumatismo. 2017;69(4):143–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum. 1984;13(4):322–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Gran JT, Myklebust G. The incidence and clinical characteristics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis: a prospective study of 231 cases. Rheumatology (Oxford). 2000;39(3):283–7.CrossRefGoogle Scholar
  11. 11.
    Guggino G, Ferrante A, Macaluso F, Triolo G, Ciccia F. Pathogenesis of polymyalgia rheumatica. Reumatismo. 2018;70(1):10–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Salvarani C, Cantini F, Olivieri I, Hunder GS. Polymyalgia rheumatica: a disorder of extraarticular synovial structures? J Rheumatol. 1999;26(3):517–21.PubMedGoogle Scholar
  13. 13.
    McGonagle D, Pease C, Marzo-Ortega H, et al. Comparison of extracapsular changes by magnetic resonance imaging in patients with rheumatoid arthritis and polymyalgia rheumatica. J Rheumatol. 2001;28:1837–41.PubMedGoogle Scholar
  14. 14.
    Camellino D, Sambuceti G, Morbelli S, Cimmino MA, Camellino D, Sambuceti G, et al. The multifaceted pathogenesis of polymyalgia rheumatica/giant cell arteritis. Arthritis Rheum. 2009;60(9):2771.CrossRefPubMedGoogle Scholar
  15. 15.
    Camellino D, Cimmino MA. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford). 2012;51(1):77–86.CrossRefGoogle Scholar
  16. 16.
    Arango M-T, Perricone C, Kivity S, Cipriano E, Ceccarelli F, Valesini G, et al. HLA-DRB1 the notorious gene in the mosaic of autoimmunity. Immunol Res. 2017;65(1):82–98.CrossRefPubMedGoogle Scholar
  17. 17.
    Marsh SGE, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291–455.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Marsh SGE. Nomenclature for factors of the HLA system, update May 2018. Hum Immunol. 2018;79(10):752–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Busch R, Kollnberger S, Mellins ED. HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications. Nat Rev Rheumatol. 2019;15(6):364–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W, et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA. 2015;313(16):1645–56.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Jacobsen S, Baslund B, Madsen HO, Tvede N, Svejgaard A, Garred P. Mannose-binding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis. J Rheumatol. 2002;29(10):2148–53.PubMedGoogle Scholar
  22. 22.
    Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol. 1998;25(11):2140–5.PubMedGoogle Scholar
  23. 23.
    González-Gay MA, García-Porrúa C, Vázquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol. 1999;26(6):1326–32.PubMedGoogle Scholar
  24. 24.
    Martínez-Taboda VM, Bartolome MJ, Lopez-Hoyos M, Blanco R, Mata C, Calvo J, et al. HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: influence on clinical subgroups and prognosis. Semin Arthritis Rheum. 2004;34(1):454–64.CrossRefPubMedGoogle Scholar
  25. 25.
    Salvarani C, Boiardi L, Mantovani V, Ranzi A, Cantini F, Olivieri I, et al. HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann Rheum Dis. 1999;58(5):303–8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol. 1996;23(1):112–9.PubMedGoogle Scholar
  27. 27.
    Alvarez-Lafuente R, Fernández-Gutiérrez B, Jover JA, Júdez E, Loza E, Clemente D, et al. Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis. 2005;64(5):780–2.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Duhaut P, Bosshard S, Calvet A, Pinede L, Demolombe-Rague S, Dumontet C, et al. Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de Recherche sur l’Artérite à Cellules Géantes. J Rheumatol. 1999;26(2):361–9.PubMedGoogle Scholar
  29. 29.
    Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64(11):3788–98.CrossRefPubMedGoogle Scholar
  30. 30.
    Dejaco C, Duftner C, Klauser A, Schirmer M. Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatica. Rheumatol Int. 2010;30(3):297–303.CrossRefPubMedGoogle Scholar
  31. 31.
    Dejaco C, Duftner C, Al-Massad J, Wagner AD, Park J-K, Fessler J, et al. NKG 2 D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2013;72(11):1852–9.CrossRefPubMedGoogle Scholar
  32. 32.
    van der Geest KSM, Abdulahad WH, Chalan P, Rutgers A, Horst G, Huitema MG, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2014;66(7):1927–38.CrossRefPubMedGoogle Scholar
  33. 33.
    Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Paluch C, Santos AM, Anzilotti C, Cornall RJ, Davis SJ. Immune checkpoints as therapeutic targets in autoimmunity. Front Immunol. 2018;9:2306.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–85.CrossRefPubMedGoogle Scholar
  36. 36.
    Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol. 2014;66(3):768–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Betrains A, Blockmans DE. Immune checkpoint inhibitor-associated polymyalgia rheumatica/giant cell arteritis occurring in a patient after treatment with nivolumab. J Clin Rheumatol. 2019.  https://doi.org/10.1097/rhu.0000000000001012 (epub ahead of print).
  39. 39.
    Robilliard B, Arnaud E, Gastaud L, Broner J. A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica. Eur J Cancer. 2018;103:281–3.CrossRefPubMedGoogle Scholar
  40. 40.
    Ward FJ, Dahal LN, Wijesekera SK, Abdul-Jawad SK, Kaewarpai T, Xu H, et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol. 2013;43(5):1274–85.CrossRefPubMedGoogle Scholar
  41. 41.
    Saverino D, Simone R, Bagnasco M, Pesce G. The soluble CTLA-4 receptor and its role in autoimmune diseases: an update. Autoimmun Highlights. 2010;1(2):73–81.CrossRefGoogle Scholar
  42. 42.
    Simone R, Brizzolara R, Chiappori A, Milintenda-Floriani F, Natale C, Greco L, et al. A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury. Int Immunol. 2009;21(9):1037–45.CrossRefPubMedGoogle Scholar
  43. 43.
    Dahal LN, Basu N, Youssef H, Khanolkar RC, Barker RN, Erwig LP, et al. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther. 2016;18(1):180.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Camellino D, Marchiano M, Pesce G, Bianchi G, Bagnasco M, Cimmino MA, et al. THU0440 soluble CTLA-4 is elevated in patients with polymyalgia rheumatica and correlates with vascular inflammation detected by PET/CT. Ann Rheum Dis. 2018;77(Suppl.):A432.Google Scholar
  45. 45.
    O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161–70.CrossRefPubMedGoogle Scholar
  46. 46.
    Watanabe R, Goronzy JJ, Berry G, Liao YJ, Weyand CM. Giant cell arteritis: from pathogenesis to therapeutic management. Curr Treat Options Rheumatol. 2016;2(2):126–37.CrossRefGoogle Scholar
  47. 47.
    Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137(18):1934–48.CrossRefPubMedGoogle Scholar
  48. 48.
    Alvarez-Rodríguez L, Lopez-Hoyos M, Mata C, Marin MJ, Calvo-Alen J, Blanco R, et al. Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis. 2010;69(1):263–9.CrossRefPubMedGoogle Scholar
  49. 49.
    García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G, Prieto-González S, Butjosa M, Segarra M, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res (Hoboken). 2010;62(6):835–41.CrossRefPubMedGoogle Scholar
  50. 50.
    Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175–87.CrossRefPubMedGoogle Scholar
  51. 51.
    Caporali R, Montecucco C, Epis O, Bobbio-Pallavicini F, Maio T, Cimmino MA. Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. Ann Rheum Dis. 2001;60(11):1021–4.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71(4):484–92.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Manzo C, Milchert M, Natale M, Brzosko M. Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis. Rheumatology (Oxford). 2019.  https://doi.org/10.1093/rheumatology/key431 (epub ahead of print).
  54. 54.
    Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum. 2000;30(1):17–24.CrossRefPubMedGoogle Scholar
  55. 55.
    Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum. 1996;39(2):304–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Baerlecken NT, Linnemann A, Gross WL, Moosig F, Vazquez-Rodriguez TR, Gonzalez-Gay MA, et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis. 2012;71(6):943–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Macchioni P, Boiardi L, Catanoso M, Pazzola G, Salvarani C. Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis. 2014;73(6):1190–3.CrossRefPubMedGoogle Scholar
  58. 58.
    Ozen G, Inanc N, Unal AU, Bas S, Kimyon G, Kisacik B, et al. Assessment of the new 2012 EULAR/ACR clinical classification criteria for polymyalgia rheumatica: a prospective multicenter study. J Rheumatol. 2016;43(5):893–900.CrossRefPubMedGoogle Scholar
  59. 59.
    Camellino D, Cimmino MA. Are the new ACR/EULAR criteria the ultimate answer for polymyalgia rheumatica classification? J Rheumatol. 2016;43(5):836–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979;38(5):434–9.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Nobunaga M, Yoshioka K, Yasuda M, Shingu M, Nobunaga M, Yoshioka K, et al. Clinical studies of polymyalgia rheumatica: a proposal of diagnostic criteria. Jpn J Med. 1989;28(4):452–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA, Schirmer M, Salvarani C, et al. Patient-reported outcomes in polymyalgia rheumatica. J Rheumatol. 2012;39(4):795–803.CrossRefPubMedGoogle Scholar
  63. 63.
    Haga HJ, Eide GE, Brun J, Johansen A, Langmark F. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20(8):1335–9.PubMedGoogle Scholar
  64. 64.
    Niccoli L, Salvarani C, Baroncelli G, Padula A, Olivieri I, Cantini F. Renal cell carcinoma mimicking polymyalgia rheumatica: clues for a correct diagnosis. Scand J Rheumatol. 2002;31(2):103–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10(11):662–70.CrossRefPubMedGoogle Scholar
  66. 66.
    Muller S, Hider S, Helliwell T, Partington R, Mallen C. The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome. Reumatismo. 2018;70(1):23–34.CrossRefPubMedGoogle Scholar
  67. 67.
    Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. Ann Oncol. 2014;25(7):1397–404.CrossRefPubMedGoogle Scholar
  68. 68.
    Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol. 2014;25(10):2025–30.CrossRefPubMedGoogle Scholar
  69. 69.
    Teunis T, Lubberts B, Reilly BT, Ring D. A systematic review and pooled analysis of the prevalence of rotator cuff disease with increasing age. J Shoulder Elbow Surg. 2014;23(12):1913–21.CrossRefPubMedGoogle Scholar
  70. 70.
    Macchioni P, Catanoso MG, Pipitone N, Boiardi L, Salvarani C. Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology. 2009;48(12):1566–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Huwart A, Garrigues F, Jousse-Joulin S, Marhadour T, Guellec D, Cornec D, et al. Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. Arthritis Res Ther. 2018;20(1):11.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Miceli MC, Zoli A, Peluso G, Bosello S, Gremese E, Ferraccioli G. Baseline shoulder ultrasonography is not a predictive marker of response to glucocorticoids in patients with polymyalgia rheumatica: a 12-month followup study. J Rheumatol. 2017;44(2):241–7.CrossRefPubMedGoogle Scholar
  73. 73.
    Fruth M, Buehring B, Baraliakos X, Braun J. Use of contrast-enhanced magnetic resonance imaging of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumatica. Clin Exp Rheumatol. 2018;36(Suppl. 114):86–95.PubMedGoogle Scholar
  74. 74.
    Owen CE, Poon AMT, Lee ST, Yap LP, Zwar RB, McMenamin CM, et al. Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica. Rheumatology (Oxford). 2018;57(2):345–53.CrossRefGoogle Scholar
  75. 75.
    Mackie SL, Pease CT, Fukuba E, Harris E, Emery P, Hodgson R, et al. Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids. Ann Rheum Dis. 2015;74(12):2188–92.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Camellino D, Dejaco C. Should 18F-FDG-PET imaging be used in the diagnosis of GCA? Nat Rev Rheumatol. 2019;5(7):388–90.CrossRefGoogle Scholar
  77. 77.
    Camellino D, Paparo F, Morbelli S, Cutolo M, Sambuceti G, Cimmino MA. Interspinous bursitis is common in polymyalgia rheumatica, but is not associated with spinal pain. Arthritis Res Ther. 2014;16(6):492.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Takahashi H, Yamashita H, Kubota K, Miyata Y, Okasaki M, Morooka M, et al. Differences in fluorodeoxyglucose positron emission tomography/computed tomography findings between elderly onset rheumatoid arthritis and polymyalgia rheumatica. Mod Rheumatol. 2015;25(4):546–51.CrossRefPubMedGoogle Scholar
  79. 79.
    Sondag M, Guillot X, Verhoeven F, Blagosklonov O, Prati C, Boulahdour H, et al. Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study. Rheumatology (Oxford). 2016;55(8):1452–7.CrossRefGoogle Scholar
  80. 80.
    Cimmino MA, Camellino D, Paparo F, Morbelli S, Massollo M, Cutolo M, et al. High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography. Rheumatology (Oxford). 2013;52(10):1865–72.CrossRefGoogle Scholar
  81. 81.
    Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford). 2007;46(4):672–7.CrossRefGoogle Scholar
  82. 82.
    Cimmino MA, Zampogna G, Parodi M. Is FDG-PET useful in the evaluation of steroid-resistant PMR patients? Rheumatology (Oxford). 2008;47(6):926–7.CrossRefGoogle Scholar
  83. 83.
    Prieto-Peña D, Martínez-Rodríguez I, Loricera J, Banzo I, Calderón-Goercke M, Calvo-Río V, et al. Predictors of positive 18 F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. Semin Arthritis Rheum. 2019;48(4):720–7.CrossRefPubMedGoogle Scholar
  84. 84.
    Slart RHJA, Writing group, Reviewer group, Members of EANM Cardiovascular, Members of EANM Infection & Inflammation, Members of Committees SC, et al. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018;45(7):1250–69.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77(5):636–43.CrossRefPubMedGoogle Scholar
  86. 86.
    Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799–807.CrossRefPubMedGoogle Scholar
  87. 87.
    Shbeeb I, Challah D, Raheel S, Crowson CS, Matteson EL. Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population. Arthritis Care Res (Hoboken). 2018;70(4):643–7.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Rheumatology. 1998;37(2):189–95.CrossRefGoogle Scholar
  89. 89.
    Cutolo M, Hopp M, Liebscher S, Dasgupta B, Buttgereit F. Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. RMD Open. 2017;3(1):e000426.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Cimmino MA, Parodi M, Caporali R, Montecucco C. Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci. 2006;1069:315–21.CrossRefPubMedGoogle Scholar
  91. 91.
    Lee JH, Choi ST, Kim JS, Yoon BY, Kwok S-K, Kim HS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int. 2013;33(6):1475–80.CrossRefPubMedGoogle Scholar
  92. 92.
    Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 1998;41(7):1221–6.CrossRefPubMedGoogle Scholar
  93. 93.
    Pulsatelli L, Boiardi L, Pignotti E, Dolzani P, Silvestri T, Macchioni P, et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk. Arthritis Rheum. 2008;59(8):1147–54.CrossRefPubMedGoogle Scholar
  94. 94.
    Charpentier A, Verhoeven F, Sondag M, Guillot X, Prati C, Wendling D. Therapeutic response to prednisone in relation to age in polymyalgia rheumatica: a comparison study. Clin Rheumatol. 2018;37(3):819–23.CrossRefPubMedGoogle Scholar
  95. 95.
    Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis. 2015;74(10):1808–17.CrossRefPubMedGoogle Scholar
  96. 96.
    Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004;141(7):493–500.CrossRefPubMedGoogle Scholar
  97. 97.
    Cimmino MA, Salvarani C, Macchioni P, Gerli R, Bartoloni Bocci E, Montecucco C, et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol. 2008;26(3):395–400.PubMedGoogle Scholar
  98. 98.
    Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. Ann Intern Med. 2007;146(9):631–9.CrossRefPubMedGoogle Scholar
  99. 99.
    Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther. 2010;12(5):R176.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Camellino D, Dejaco C. Update on treatment of polymyalgia rheumatica. Reumatismo. 2018;70(1):59–66.CrossRefPubMedGoogle Scholar
  101. 101.
    Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–28.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Devauchelle-Pensec V, Berthelot JM, Cornec D, Renaudineau Y, Marhadour T, Jousse-Joulin S, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75(8):1506–10.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004;63(10):1279–83.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Lally L, Forbess L, Hatzis C, Spiera R. Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol. 2016;68(10):2550–4.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Matteson EL, Dasgupta B, Schmidt WA, Salvarani C, Gendi N, Galeazzi M, et al. A 2 week single-blind, randomized, 3-arm proof of concept study of the effects of secukinumab (anti-IL17 mAb), canakinumab (anti-IL-1 b mAb), or corticosteroids on initial disease activity scores in patients with PMR, followed by an open-label extension. Arthritis Rheumatol. 2014;66(10):S391.Google Scholar
  106. 106.
    Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005;32(1):65–73.PubMedGoogle Scholar
  107. 107.
    Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS, et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis. 2010;70(3):447–53.CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–37.CrossRefPubMedGoogle Scholar
  109. 109.
    Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;39(10):1873–8.CrossRefGoogle Scholar
  110. 110.
    Lai LYH, Harris E, West RM, Mackie SL. Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis. RMD Open. 2018;4(1):e000521.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Partington R, Helliwell T, Muller S, Abdul Sultan A, Mallen C. Comorbidities in polymyalgia rheumatica: a systematic review. Arthritis Res Ther. 2018;20(1):258.CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Chatzigeorgiou C, Mackie SL. Comorbidity in polymyalgia rheumatica. Reumatismo. 2018;70(1):35–43.CrossRefPubMedGoogle Scholar
  113. 113.
    Paskins Z, Whittle R, Sultan AA, Muller S, Blagojevic-Bucknall M, Helliwell T, et al. Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study. BMC Med. 2018;16(1):4.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Rossini M, Viapiana O, Vitiello M, Malavolta N, La Montagna G, Maddali Bongi S, et al. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo. 2017;69(1):30–9.CrossRefPubMedGoogle Scholar
  115. 115.
    De Lorenzi C, Rosa GM, Camellino D, Morbelli S, Dorighi U, Masoero G, et al. Cardiac and aortic involvement in patients with polymyalgia rheumatica: a study with echocardiography and FDG-PET/CT. Clin Exp Rheumatol. 2017;35(Suppl. 103(1)):224.PubMedGoogle Scholar
  116. 116.
    Marin Zucaro NM, Scolnik M, Mollerach FB, Scaglioni V, Lo Giudice LF, Martinez PJM, Jaramillo Gallego JF, Soriano ER. Development of thoracic aortic aneurysms in patients with polymyalgia rheumatica: underdiagnosed giant cell arteritis?. Arthritis Rheumatol. 2018;70(suppl 10). https://acrabstracts.org/abstract/development-of-thoracic-aortic-aneurysms-in-patients-with-polymyalgia-rheumatica-underdiagnosed-giant-cell-arteritis/. Accessed 24 Aug 2019.
  117. 117.
    Mackie SL, Hensor EMA, Morgan AW, Pease CT. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis. 2014;73(1):143–8.CrossRefPubMedGoogle Scholar
  118. 118.
    Kermani TA, Diab S, Sreih AG, Cuthbertson D, Borchin R, Carette S, et al. Arterial lesions in giant cell arteritis: a longitudinal study. Semin Arthritis Rheum. 2019;48(4):707–13.CrossRefPubMedGoogle Scholar
  119. 119.
    Twohig H, Mitchell C, Mallen C, Adebajo A, Mathers N. “I suddenly felt I’d aged”: a qualitative study of patient experiences of polymyalgia rheumatica (PMR). Patient Educ Couns. 2015;98(5):645–50.CrossRefPubMedGoogle Scholar
  120. 120.
    Camellino D, Dejaco C, Buttgereit F, Matteson EL. Treat to target: a valid concept for management of polymyalgia rheumatica and giant cell arteritis? Rheum Dis Clin N Am. 2019;45(4) (in press).Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of RheumatologyLa Colletta Hospital, Azienda Sanitaria Locale 3ArenzanoItaly
  2. 2.Autoimmunology Laboratory, Department of Internal MedicineUniversity of GenoaGenoaItaly
  3. 3.Dienst für Rheumatologie, Servizio di reumatologia, Südtiroler Sanitätsbetrieb, Azienda Sanitaria dell’Alto Adige, Krankenhaus Bruneck, Ospedale di BrunicoBruneckItaly
  4. 4.Department of RheumatologyMedical University GrazGrazAustria

Personalised recommendations